DEC2在乳腺癌组织中的表达及临床意义  

Expression of DEC2 in breast cancer and its clinical significance

作　　者：陈靓昱 王志鹏[1] 王慧 张清媛[2] CHEN Jing-yu;WANG Zhi-peng;WANG Hui;ZHANG Qing-yuan(Department of Medical Oncology,The Fourth Affiliated Hospital of Harbin Medical Universi- ty,Harbin 150001,China;Department of Medical Oncology,Cancer Hospital of Harbin Medical University,Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属第四医院肿瘤内科,黑龙江哈尔滨150001 [2]哈尔滨医科大学附属肿瘤医院肿瘤内科,黑龙江哈尔滨150081

出　　处：《哈尔滨医科大学学报》2018年第4期322-325,共4页Journal of Harbin Medical University

基　　金：哈尔滨医科大学附属第四医院杰出青年基金面上项目(HYDSYJQ201508);黑龙江省政府博士后基金资助项目(LBH-Z15142)

摘　　要：目的研究分化型胚胎软骨发育基因(Sharp1,又名DEC2)在乳腺癌组织中的表达情况,探讨其在乳腺癌侵袭和转移中的作用及对乳腺癌预后的判断价值。方法应用SP法,对135例浸润性乳腺癌患者的原发灶及其中38例患者转移灶进行免疫组化检测。采用Spearman法分析DEC2表达与乳腺癌临床病理特征的关系,根据随访资料分析DEC2表达与复发转移的关系;采用Kaplan-Meire法绘制生存曲线并行Log-Rank检验。结果 DEC2的表达与淋巴结转移情况、临床分期、p53突变呈负相关;与乳腺癌复发转移呈负相关。DEC2低表达组患者生存时间显著低于高表达组患者。结论 DEC2可作为判断乳腺癌预后的重要指标,有望成为未来乳腺癌治疗的新靶点,从而为抑制乳腺癌复发转移的药物的研制奠定理论基础。Objective To investigate the expression of the enhancer of differentiated embryochondrocyte expressed gene 2（DEC2） in breast cancer; To explore the development of the role of DEC2 in breast cancer and the clinical value in predicting prognosis. Methods Immunohistochemistry was used to detect the expression of DEC2 in 135 cases of invasive ductal carcinoma from breast cancer,and 38 cases of metastasesand among them. All the patients were followed up. The Spearman method was used to analyze the relationship between DEC2 expression and clinicopathological features,recurrence and metastasis of breast cancer,and Kaplan-Meire method was used to draw survival curves. Results The expression of DEC2 was negatively correlated with lymph node metastasis,clinical stage and p53,and was negatively correlated with the recurrence and metastasis of breast cancer. The survival of the DEC2 low expression group was significantly shorter than that of the high expression group. Conclusion DEC2 expects to become a new target for treatment of breast cancer,so as to lay the theoretical foundation for the development of breast cancer recurrence and metastasis inhibiting drugs.

关 键 词：DEC2 乳腺癌 生存 预后 免疫组化 

分 类 号：R737.9[医药卫生—肿瘤]